Plain-English translation of NCT07572812 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Epilepsy research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which involves transplanting special brain cells into the brain through surgery to help control severe epilepsy that hasn't responded to medication. The goal is to see if this innovative approach can reduce seizures and improve quality of life for people with drug-resistant temporal lobe epilepsy. Researchers will monitor participants closely for 24 months to understand how safe and effective this treatment is.
Many people with epilepsy continue to have seizures even after trying multiple anti-seizure medications. This trial exists to explore a completely new approach—using regenerated brain cells to address the root cause of the seizures rather than just managing symptoms with drugs.
You likely qualify if…
You likely don't qualify if…
If accepted, you would undergo brain surgery to receive the cell transplant, followed by medications to help your immune system tolerate the new cells. Over the next 24 months, you would have regular clinic visits, brain imaging scans, blood tests, and mood and thinking assessments. You would also keep a daily seizure diary and report any side effects, allowing doctors to carefully track your safety and whether the treatment is helping reduce your seizures.
AI-generated summary from trial data · Nov 18, 2026 · Not medical advice
China